Considering OVCAR-3 cells are cisplatin-resistant and p53-mutant, the current results implicated that TF3 might have the potential to be applied in the treatment of cisplatin-resistant and p53-mutant ovarian cancer. This evidence concerns the gene TP53 and ovarian cancer.